Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 15/20 | 0.66 |
| ▸ | DRD3 | P35462 | 15/20 | 0.66 |
| ▸ | DRD4 | P21917 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3389069 | 0.88 | DRD2 (0.60) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6343702 | 0.83 | DRD3 (0.66) | DRD2DRD3DRD4 | |
| SCHEMBL7568447 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29460204 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL29448457 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL8930123 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL623950 | 0.81 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| Bromide SCHEMBL4204027 | 0.80 | DRD2 (1.00) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL6335402 | 0.79 | DRD2 (0.66) | DRD2DRD3DRD4MEN1KMT2A | |
| SCHEMBL9851528 | 0.78 | HTR1A (0.57) | DRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627644-B2 | Muscarinic receptor antagonists and parasympathetic nervous system. The physiological actions of Acetylcholine are mediated by activation of either nicotinic or muscarinic receptors | SYNTEX (U.S.A.) LLC | 2003-09-30 | — | — | US | disclosed |
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | SYNTEX (U.S.A.) LLC, NAME CHANGED TO ROCHE PALO ALTO LLC | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162780-A1 | 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM1, CHRM3, CHRM2 | DRD2 50/4885DRD3 56/4885DRD4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.